Joanna Roder

816 total citations
36 papers, 466 citations indexed

About

Joanna Roder is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joanna Roder has authored 36 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Joanna Roder's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Joanna Roder is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Joanna Roder collaborates with scholars based in United States, Italy and Germany. Joanna Roder's co-authors include Heinrich Röder, Julia Grigorieva, David P. Carbone, Lesley Seymour, Keyue Ding, Frances A. Shepherd, Ming‐Sound Tsao, Krista Meyer, Carlos Oliveira and Robert W. Georgantas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Joanna Roder

33 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joanna Roder United States	13	260	219	145	97	81	36	466
Sarah Gerster Switzerland	7	415 1.6×	170 0.8×	164 1.1×	58 0.6×	84 1.0×	7	638
Julia Grigorieva United States	13	336 1.3×	293 1.3×	208 1.4×	133 1.4×	124 1.5×	38	579
Michał Marczyk Poland	17	167 0.6×	155 0.7×	425 2.9×	63 0.6×	272 3.4×	69	786
Shalini Makawita United States	11	242 0.9×	113 0.5×	238 1.6×	117 1.2×	103 1.3×	22	545
Emma Niméus Sweden	16	268 1.0×	118 0.5×	378 2.6×	216 2.2×	310 3.8×	40	816
Edmund H. Wilkes United Kingdom	12	175 0.7×	53 0.2×	328 2.3×	90 0.9×	110 1.4×	25	625
Franziska Erlmeier Germany	12	197 0.8×	132 0.6×	304 2.1×	222 2.3×	107 1.3×	28	612
A. Huijbers Netherlands	6	213 0.8×	61 0.3×	75 0.5×	33 0.3×	75 0.9×	8	343
Michelle Palmieri Australia	11	201 0.8×	31 0.1×	167 1.2×	52 0.5×	51 0.6×	19	395
Jang Ho Cho South Korea	12	427 1.6×	462 2.1×	174 1.2×	21 0.2×	131 1.6×	29	645

Countries citing papers authored by Joanna Roder

Since Specialization

Citations

This map shows the geographic impact of Joanna Roder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna Roder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna Roder more than expected).

Fields of papers citing papers by Joanna Roder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanna Roder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna Roder. The network helps show where Joanna Roder may publish in the future.

Co-authorship network of co-authors of Joanna Roder

This figure shows the co-authorship network connecting the top 25 collaborators of Joanna Roder. A scholar is included among the top collaborators of Joanna Roder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna Roder. Joanna Roder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koc, Matthew A., Timothy A. Wiles, Amanda L. Weaver, et al.. (2023). Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance. SHILAP Revista de lepidopterología. 30. 51–60. 3 indexed citations

Roder, Joanna, et al.. (2021). Explaining multivariate molecular diagnostic tests via Shapley values. BMC Medical Informatics and Decision Making. 21(1). 211–211. 18 indexed citations

Muscarella, Peter, Tanios Bekaii‐Saab, Kristi McIntyre, et al.. (2021). A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. SHILAP Revista de lepidopterología. 7(1). 8–19. 17 indexed citations

Campbell, T., Heinrich Röder, Samantha MaWhinney, et al.. (2021). Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data. International Journal of Medical Informatics. 155. 104594–104594. 16 indexed citations

Mahalingam, Devalingam, Leonidas Chelis, Sunyoung S. Lee, et al.. (2021). Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test. Cancers. 13(13). 3109–3109. 5 indexed citations

Muller, Mirte, Karlijn Hummelink, Daan P. Hurkmans, et al.. (2020). A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(19). 5188–5197. 17 indexed citations

Kasimir‐Bauer, Sabine, Joanna Roder, Eva Obermayr, et al.. (2020). Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer. Cancers. 12(9). 2519–2519. 2 indexed citations

Roder, Joanna, Carlos Oliveira, Krista Meyer, et al.. (2020). A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. PubMed. 18. 13–26. 1 indexed citations

Davis, Andrew A., Jonghanne Park, Wade T. Iams, et al.. (2020). Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer. Cancer Research. 80(16_Supplement). 5527–5527. 1 indexed citations

10.

Grigorieva, Julia, et al.. (2019). Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests. 15. 44–53. 11 indexed citations

11.

Buttigliero, Consuelo, Frances A. Shepherd, Fabrice Barlési, et al.. (2018). Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The Oncologist. 24(6). e251–e259. 10 indexed citations

12.

Fidler, Mary J., Cristina Fhied, Joanna Roder, et al.. (2018). The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 18(1). 310–310. 32 indexed citations

13.

Weber, Jeffrey S., Mario Sznol, Ryan J. Sullivan, et al.. (2017). A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research. 6(1). 79–86. 53 indexed citations

14.

Grossi, Francesco, Carlo Genova, Erika Rijavec, et al.. (2017). Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 117. 64–69. 12 indexed citations

15.

Grossi, Francesco, Erika Rijavec, Carlo Genova, et al.. (2016). Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. British Journal of Cancer. 116(1). 36–43. 16 indexed citations

16.

Stinchcombe, Thomas E., Joanna Roder, Amy H. Peterman, et al.. (2013). A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(4). 443–451. 41 indexed citations

17.

Carbone, David P., Keyue Ding, Heinrich Röder, et al.. (2012). Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. Journal of Thoracic Oncology. 7(11). 1653–1660. 84 indexed citations

18.

Gautschi, Oliver, Anne‐Marie C. Dingemans, Susanne Crowe, et al.. (2012). VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528. Lung Cancer. 79(1). 59–64. 25 indexed citations

19.

Bowlus, Christopher L., Erin H. Seeley, Joanna Roder, et al.. (2011). In situ mass spectrometry of autoimmune liver diseases. Cellular and Molecular Immunology. 8(3). 237–242. 10 indexed citations

20.

Roder, Joanna, Heinrich Röder, Julia Grigorieva, et al.. (2011). S1-4: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®).. Cancer Research. 71(24_Supplement). S1–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact